Clinical and Molecular Effects of N-Acetylcysteine Treatment in COVID-19-Related Acute Respiratory Distress Syndrome

Prospective, randomized, double-blind, placebo-controlled clinical trial evaluating the clinical and molecular effects of intravenous N-acetylcysteine (NAC) in patients with COVID-19-associated acute respiratory distress syndrome (ARDS) treated in the intensive care unit. The study assessed inflammatory and thromboinflammatory biomarkers, hypoxia-related gene expression (HIF-1α, ACE2, CD147), and clinical outcomes including mortality and length of ICU stay.

NCT Number	NCT07374991
Lead Sponsor	University of Gaziantep
Conditions	COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS)
Enrollment	59 participants
Start Date	2020-11-01
Primary Completion	2022-06-10 (estimated)
Study Completion	2022-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-01-29